293 research outputs found

    In vivo MRI based prostate cancer localization with random forests and auto-context model

    Get PDF
    Prostate cancer is one of the major causes of cancer death for men. Magnetic resonance (MR) imaging is being increasingly used as an important modality to localize prostate cancer. Therefore, localizing prostate cancer in MRI with automated detection methods has become an active area of research. Many methods have been proposed for this task. However, most of previous methods focused on identifying cancer only in the peripheral zone (PZ), or classifying suspicious cancer ROIs into benign tissue and cancer tissue. Few works have been done on developing a fully automatic method for cancer localization in the entire prostate region, including central gland (CG) and transition zone (TZ). In this paper, we propose a novel learning-based multi-source integration framework to directly localize prostate cancer regions from in vivo MRI. We employ random forests to effectively integrate features from multi-source images together for cancer localization. Here, multi-source images include initially the multi-parametric MRIs (i.e., T2, DWI, and dADC) and later also the iteratively-estimated and refined tissue probability map of prostate cancer. Experimental results on 26 real patient data show that our method can accurately localize cancerous sections. The higher section-based evaluation (SBE), combined with the ROC analysis result of individual patients, shows that the proposed method is promising for in vivo MRI based prostate cancer localization, which can be used for guiding prostate biopsy, targeting the tumor in focal therapy planning, triage and follow-up of patients with active surveillance, as well as the decision making in treatment selection. The common ROC analysis with the AUC value of 0.832 and also the ROI-based ROC analysis with the AUC value of 0.883 both illustrate the effectiveness of our proposed method

    MRI-based prostate cancer detection with high-level representation and hierarchical classification

    Get PDF
    Extracting the high-level feature representation by using deep neural networks for detection of prostate cancer, and then based on high-level feature representation constructing hierarchical classification to refine the detection results

    An Investigation of Methods for CT Synthesis in MR-only Radiotherapy

    Get PDF

    Improving the Clinical Use of Magnetic Resonance Spectroscopy for the Analysis of Brain Tumours using Machine Learning and Novel Post-Processing Methods

    Get PDF
    Magnetic Resonance Spectroscopy (MRS) provides unique and clinically relevant information for the assessment of several diseases. However, using the currently available tools, MRS processing and analysis is time-consuming and requires profound expert knowledge. For these two reasons, MRS did not gain general acceptance as a mainstream diagnostic technique yet, and the currently available clinical tools have seen little progress during the past years. MRS provides localized chemical information non-invasively, making it a valuable technique for the assessment of various diseases and conditions, namely brain, prostate and breast cancer, and metabolic diseases affecting the brain. In brain cancer, MRS is normally used for: (1.) differentiation between tumors and non-cancerous lesions, (2.) tumor typing and grading, (3.) differentiation between tumor-progression and radiation necrosis, and (4.) identification of tumor infiltration. Despite the value of MRS for these tasks, susceptibility differences associated with tissue-bone and tissue-air interfaces, as well as with the presence of post-operative paramagnetic particles, affect the quality of brain MR spectra and consequently reduce their clinical value. Therefore, the proper quality management of MRS acquisition and processing is essential to achieve unambiguous and reproducible results. In this thesis, special emphasis was placed on this topic. This thesis addresses some of the major problems that limit the use of MRS in brain tumors and focuses on the use of machine learning for the automation of the MRS processing pipeline and for assisting the interpretation of MRS data. Three main topics were investigated: (1.) automatic quality control of MRS data, (2.) identification of spectroscopic patterns characteristic of different tissue-types in brain tumors, and (3.) development of a new approach for the detection of tumor-related changes in GBM using MRSI data. The first topic tackles the problem of MR spectra being frequently affected by signal artifacts that obscure their clinical information content. Manual identification of these artifacts is subjective and is only practically feasible for single-voxel acquisitions and in case the user has an extensive experience with MRS. Therefore, the automatic distinction between data of good or bad quality is an essential step for the automation of MRS processing and routine reporting. The second topic addresses the difficulties that arise while interpreting MRS results: the interpretation requires expert knowledge, which is not available at every site. Consequently, the development of methods that enable the easy comparison of new spectra with known spectroscopic patterns is of utmost importance for clinical applications of MRS. The third and last topic focuses on the use of MRSI information for the detection of tumor-related effects in the periphery of brain tumors. Several research groups have shown that MRSI information enables the detection of tumor infiltration in regions where structural MRI appears normal. However, many of the approaches described in the literature make use of only a very limited amount of the total information contained in each MR spectrum. Thus, a better way to exploit MRSI information should enable an improvement in the detection of tumor borders, and consequently improve the treatment of brain tumor patients. The development of the methods described was made possible by a novel software tool for the combined processing of MRS and MRI: SpectrIm. This tool, which is currently distributed as part of the jMRUI software suite (www.jmrui.eu), is ubiquitous to all of the different methods presented and was one of the main outputs of the doctoral work. Overall, this thesis presents different methods that, when combined, enable the full automation of MRS processing and assist the analysis of MRS data in brain tumors. By allowing clinical users to obtain more information from MRS with less effort, this thesis contributes to the transformation of MRS into an important clinical tool that may be available whenever its information is of relevance for patient management

    A review of artificial intelligence in prostate cancer detection on imaging

    Get PDF
    A multitude of studies have explored the role of artificial intelligence (AI) in providing diagnostic support to radiologists, pathologists, and urologists in prostate cancer detection, risk-stratification, and management. This review provides a comprehensive overview of relevant literature regarding the use of AI models in (1) detecting prostate cancer on radiology images (magnetic resonance and ultrasound imaging), (2) detecting prostate cancer on histopathology images of prostate biopsy tissue, and (3) assisting in supporting tasks for prostate cancer detection (prostate gland segmentation, MRI-histopathology registration, MRI-ultrasound registration). We discuss both the potential of these AI models to assist in the clinical workflow of prostate cancer diagnosis, as well as the current limitations including variability in training data sets, algorithms, and evaluation criteria. We also discuss ongoing challenges and what is needed to bridge the gap between academic research on AI for prostate cancer and commercial solutions that improve routine clinical care

    Radiomics in prostate cancer: an up-to-date review

    Get PDF
    : Prostate cancer (PCa) is the most common worldwide diagnosed malignancy in male population. The diagnosis, the identification of aggressive disease, and the post-treatment follow-up needs a more comprehensive and holistic approach. Radiomics is the extraction and interpretation of images phenotypes in a quantitative manner. Radiomics may give an advantage through advancements in imaging modalities and through the potential power of artificial intelligence techniques by translating those features into clinical outcome prediction. This article gives an overview on the current evidence of methodology and reviews the available literature on radiomics in PCa patients, highlighting its potential for personalized treatment and future applications

    Prostate cancer radiogenomics—from imaging to molecular characterization

    Get PDF
    Radiomics and genomics represent two of the most promising fields of cancer research, designed to improve the risk stratification and disease management of patients with prostate cancer (PCa). Radiomics involves a conversion of imaging derivate quantitative features using manual or automated algorithms, enhancing existing data through mathematical analysis. This could increase the clinical value in PCa management. To extract features from imaging methods such as magnetic resonance imaging (MRI), the empiric nature of the analysis using machine learning and artificial intelligence could help make the best clinical decisions. Genomics information can be explained or decoded by radiomics. The development of methodologies can create more-efficient predictive models and can better characterize the molecular features of PCa. Additionally, the identification of new imaging biomarkers can overcome the known heterogeneity of PCa, by non-invasive radio-logical assessment of the whole specific organ. In the future, the validation of recent findings, in large, randomized cohorts of PCa patients, can establish the role of radiogenomics. Briefly, we aimed to review the current literature of highly quantitative and qualitative results from well-de-signed studies for the diagnoses, treatment, and follow-up of prostate cancer, based on radiomics, genomics and radiogenomics research

    Artificial intelligence in cancer imaging: Clinical challenges and applications

    Get PDF
    Judgement, as one of the core tenets of medicine, relies upon the integration of multilayered data with nuanced decision making. Cancer offers a unique context for medical decisions given not only its variegated forms with evolution of disease but also the need to take into account the individual condition of patients, their ability to receive treatment, and their responses to treatment. Challenges remain in the accurate detection, characterization, and monitoring of cancers despite improved technologies. Radiographic assessment of disease most commonly relies upon visual evaluations, the interpretations of which may be augmented by advanced computational analyses. In particular, artificial intelligence (AI) promises to make great strides in the qualitative interpretation of cancer imaging by expert clinicians, including volumetric delineation of tumors over time, extrapolation of the tumor genotype and biological course from its radiographic phenotype, prediction of clinical outcome, and assessment of the impact of disease and treatment on adjacent organs. AI may automate processes in the initial interpretation of images and shift the clinical workflow of radiographic detection, management decisions on whether or not to administer an intervention, and subsequent observation to a yet to be envisioned paradigm. Here, the authors review the current state of AI as applied to medical imaging of cancer and describe advances in 4 tumor types (lung, brain, breast, and prostate) to illustrate how common clinical problems are being addressed. Although most studies evaluating AI applications in oncology to date have not been vigorously validated for reproducibility and generalizability, the results do highlight increasingly concerted efforts in pushing AI technology to clinical use and to impact future directions in cancer care
    • …
    corecore